研究

A. Hamada, H. Oizumi, H. Kato, J. Suzuki, K. Nakahashi, S. Takamori, R. Sho and M. Sadahiro

Outcome of thoracoscopic anatomical sublobar resection under 3-dimensional computed tomography simulation

A. Hamada, K. Suda, T. Koga, T. Fujino, M. Nishino, S. Ohara, M. Chiba, M. Shimoji, T. Takemoto, J. Soh, T. Uchida and T. Mitsudomi

In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial

T. Fujino, K. Suda, K.Sakai, I. Murakami, S. Shimizu, S. Ohara, T. Koga, A. Hamada, J. Soh, K. Nishio, and T. Mitsudomi.

Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas

T. Koga, K. Suda, M. Nishino, T. Fujino, S. Ohara, A. Hamada, J. Soh, V. Tirunagaru, A. Vellanki, R. C. Doebele and T. Mitsudomi

Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study

K. Suda

Recent Advances in Cancer Immunotherapy

K. Suda, S. Ohara, T. Fujino, A. Hamada, M Chiba, M. Shimoji, T. Takemoto, J. Soh and T. Mitsudomi

Frequent EGFR Mutations and Better Prognosis in Positron Emission Tomography-Negative, Solid-Type Lung Cancer

J. Soh, S. Sugimoto, K. Namba, A. Miura, T. Shiotani, H. Yamamoto, K. Suzawa, K. Shien, H. Yamamoto, M. Okazaki, K. Katsui, M. Yamane, K. Kiura, S. Kanazawa and S. Toyooka

Chronic Lung Injury After Trimodality Therapy for Locally Advanced Non-Small Cell Lung Cancer

H. Tada, T. Mitsudomi, T. Misumi, K. Sugio, M. Tsuboi, I. Okamoto, Y. Iwamoto, N. Sakakura, S. Sugawara, S. Atagi, T. Takahashi, H. Hayashi, M. Okada, H. Inokawa, H. Yoshioka, K. Takahashi, M. Higashiyama, I. Yoshino, K. Nakagawa and G. West Japan Oncology

Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT)

T. Fujino and T. Mitsudomi

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor

T. Fujino, K. Suda and T. Mitsudomi

Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges

A. Hamada, J. Soh, A. Hata, K. Nakamatsu, M. Shimokawa, Y. Yatabe, H. Oizumi, M. Tsuboi, H. Horinouchi, I. Yoshino, M. Tanahashi, S. Toyooka, M. Okada, H. Yokomise, M. Yamashita, Y. Nishimura, N. Yamamoto, K. Nakagawa and T. Mitsudomi

Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L)

A. Hamada, J. Soh and T. Mitsudomi

Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer

T. Koga, K. Suda, T. Fujino, S. Ohara, A. Hamada, M. Nishino, M. Chiba, M. Shimoji, T. Takemoto, T. Arita, M. Gmachl, M. H. Hofmann, J. Soh and T. Mitsudomi

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments

T. Koga, K. Suda, T. Fujino, S. Ohara, A. Hamada, M. Nishino, M. Chiba, M. Shimoji, T. Takemoto, T. Arita, M. Gmachl, M. H. Hofmann, J. Soh and T. Mitsudomi

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments

T. Mitsudomi and J. Soh

Adjuvant therapy of operable nonsmall cell lung cancer: an update

M. Nishino, K. Suda, T. Koga, S. Ohara, T. Fujino, J. Soh, V. Tirunagaru, A. Vellanki, R. C. Doebele and T. Mitsudomi

Activity of tarloxotinib-E in cells with EGFR exon-20 insertion mutations and mechanisms of acquired resistance

S. Ohara, K. Suda, T. Fujino, A. Hamada, T. Koga, M. Nishino, M. Chiba, M. Shimoji, T. Takemoto, J. Soh and T. Mitsudomi

Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer

S. Ohara, K. Suda and T. Mitsudomi

Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers-Applications and Limitations

J. Soh, A. Hamada, T. Fujino and T. Mitsudomi

Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors

K. Suda

Recent Advances in Cancer Immunotherapy

K. Suda and T. Mitsudomi

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations

K. Suda, T. Mitsudomi, Y. Shintani, J. Okami, H. Ito, T. Ohtsuka, S. Toyooka, T. Mori, S. I. Watanabe, H. Asamura, M. Chida, H. Date, S. Endo, T. Nagayasu, R. Nakanishi, E. Miyaoka, M. Okumura, I. Yoshino and R. Japanese Joint Committee of Lung Cancer

Clinical Impacts of EGFR Mutation Status: Analysis of 5780 Surgically Resected Lung Cancer Cases

K. Suda, K. Sakai, K. Obata, S. Ohara, T. Fujino, T. Koga, A. Hamada, J. Soh, K. Nishio and T. Mitsudomi

Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five Cases

T. Takemoto, J. Soh, S. Ohara, T. Fujino, T. Koga, M. Nishino, A. Hamada, M. Chiba, M. Shimoji, K. Suda, K. Tomizawa and T. Mitsudomi

The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgery